Europe Genetic Testing Market - Industry Trends and Forecast to 2029

Description

List of Tables

Europe genetic testing market is projected to register a CAGR of 14.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Europe Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive And Presymptomatic Testing, Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, Other Diseases) End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, Private Laboratories), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Europe genetic testing market are:

High prevalence of dental disorders
Increasing research and development

Market Players:

The key market players for Europe genetic testing market are listed below:

Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Illumina, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Myriad Genetics, Inc.
Abbott
Eurofins Scientific
Biocartis
Cepheid ( A subsidiary of Danaher)
PacBio
BioReference
Natera, Inc.
Others

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES

4.3 STRATEGIC INITIATIVES:

4.4 CONCLUSION:

4.5 INDUSTRY INSIGHTS
- 4.5.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
- 4.5.2 GENETIC TESTS PRICING
- 4.5.3 KEY INSIGHTS

5 EPIDERMIOLOGY

6 EUROPE GENETIC TESTING MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS
- 7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
- 7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
- 7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER
- 7.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
7.2 RESTRAINTS
- 7.2.1 HIGH COST OF GENETIC TESTING
- 7.2.2 CYBER SECURITY CONCERNS IN GENOMICS
7.3 OPPORTUNITIES
- 7.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
- 7.3.2 TECHNOLOGICAL ADVANCEMENT
- 7.3.3 INCREASING RESEARCH AND DEVELOPMENT
- 7.3.4 RISING DISPOSABLE INCOME
7.4 CHALLENGES
- 7.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
- 7.4.2 STRINGENT REGULATION POLICY

8 EUROPE GENETIC TESTING MARKET, BY TYPE

8.1 OVERVIEW
8.2 DIAGNOSTIC TESTING
8.3 PRENATAL TESTING
- 8.3.1 NON-INVASIVE SCREENING
  - 8.3.1.1 BY SCREENING METHOD
    - 8.3.1.1.1 WHOLE GENOME SEQUENCING
    - 8.3.1.1.2 COUNTING OF CFDNA FRAGMENTS
    - 8.3.1.1.3 OTHERS
  - 8.3.1.2 BY CONDITION
    - 8.3.1.2.1 TRISOMY 21
    - 8.3.1.2.2 KLINEFELTER SYNDROME
    - 8.3.1.2.3 JACOBS SYNDROME
    - 8.3.1.2.4 CYSTIC FIBROSIS
    - 8.3.1.2.5 TURNER SYNDROME
    - 8.3.1.2.6 TRISOMY 18
    - 8.3.1.2.7 HEMOPHILIA
    - 8.3.1.2.8 TRISOMY 13
    - 8.3.1.2.9 MICRODELETION SYNDROME
    - 8.3.1.2.10 FETAL GENDER
    - 8.3.1.2.11 OTHERS
  - 8.3.1.3 BY SCREENING TYPE
    - 8.3.1.3.1 CARRIER SEQUENCING
    - 8.3.1.3.2 SEQUENTIAL SEQUENCING
- 8.3.2 MATERNAL SERUM QUAD SCREENING
8.4 NEW BORN SCREENING
8.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
8.6 CARRIER TESTING
- 8.6.1 BY TEST TYPE
  - 8.6.1.1 MOLECULAR SCREENING TEST
  - 8.6.1.2 BIOCHEMICAL SCREENING TEST
- 8.6.2 BY TYPE
  - 8.6.2.1 EXPANDED CARRIER SCREENING
    - 8.6.2.1.1 PREDESIGNED PANEL TESTING
    - 8.6.2.1.2 CUSTOM-MADE PANEL TESTING
  - 8.6.2.2 TARGETED DISEASE CARRIER SCREENING
    - 8.6.2.2.1 BY MEDICAL CONDITION
    - 8.6.2.2.2 HEMATOLOGICAL CONDITIONS
    - 8.6.2.2.3 PULMONARY CONDITIONS
    - 8.6.2.2.4 NEUROLOGICAL CONDITIONS
    - 8.6.2.2.5 OTHER CONDITIONS
8.7 OTHER TYPES

9 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY

9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION
- 9.2.1 REAL-TIME PCR (QPCR)
- 9.2.2 DIGITAL PCR (DPCR)
- 9.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
- 9.2.4 HOT-START PCR
- 9.2.5 MULTIPLEX PCR
- 9.2.6 OTHER PCR
9.3 DNA SEQUENCING (NGS-BASED TESTING)
- 9.3.1 NEXT GENERATION SEQUENCING (NGS)
- 9.3.2 SANGER SEQUENCING (SINGLE GENE)
- 9.3.3 OTHER
9.4 WHOLE GENOME SEQUENCING
9.5 MICROARRAYS
- 9.5.1 DNA MICROARRAYS
- 9.5.2 PROTEIN MICROARRAYS
- 9.5.3 OTHER MICROARRAYS
9.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
9.7 OTHERS

10 EUROPE GENETIC TESTING MARKET, BY DISEASES

10.1 OVERVIEW
10.2 CANCER
- 10.2.1 BREAST
- 10.2.2 COLON
- 10.2.3 LUNG
- 10.2.4 PROSTATE
- 10.2.5 OTHERS
10.3 SICKLE CELL ANEMIA
10.4 THALASSEMIA
10.5 RARE GENETIC DISORDER
- 10.5.1 TRISOMY 21
- 10.5.2 MONOSOMY X
- 10.5.3 TRISOMY 13
- 10.5.4 MICRODELETION SYNDROME
- 10.5.5 TRISOMY 18
- 10.5.6 OTHERS
10.6 FRAGILE X SYNDROME
10.7 DUCHENNE MUSCULAR DYSTROPHY
10.8 HUNTINGTON'S DISEASE
10.9 CYSTIC FIBROSIS
10.10 OTHERS

11 EUROPE GENETIC TESTING MARKET, BY END USER

11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 PRIVATE CLINICS
11.6 LABORATORY SERVICE PROVIDERS
11.7 PRIVATE LABORATORIES

12 EUROPE GENETIC TESTING MARKET, BY REGION

12.1 EUROPE
- 12.1.1 GERMANY
- 12.1.2 FRANCE
- 12.1.3 U.K.
- 12.1.4 RUSSIA
- 12.1.5 ITALY
- 12.1.6 SPAIN
- 12.1.7 TURKEY
- 12.1.8 NETHERLANDS
- 12.1.9 SWITZERLAND
- 12.1.10 BELGIUM
- 12.1.11 REST OF EUROPE

13 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 WOT ANALYSIS

15 COMPANY PROFILE

15.1 ILLUMINA, INC.
- 15.1.1 COMPANY SNAPSHOT
- 15.1.2 COMPANY SHARE ANALYSIS
- 15.1.3 PRODUCT PORTFOLIO
- 15.1.4 RECENT DEVELOPMENT
  - 15.1.4.1 ACQUISITION
  - 15.1.4.2 COLLABORATION
15.2 CEPHEID
- 15.2.1 COMPANY SNAPSHOT
- 15.2.2 REVENUE ANALYSIS
- 15.2.3 COMPANY SHARE ANALYSIS
- 15.2.4 PRODUCT PORTFOLIO
- 15.2.5 RECENT DEVELOPMENT
  - 15.2.5.1 BUSINEES EXPANSION
15.3 FULGENT GENETICS
- 15.3.1 COMPANY SNAPSHOT
- 15.3.2 REVENUE ANALYSIS
- 15.3.3 COMPANY SHARE ANALYSIS
- 15.3.4 PRODUCT PORTFOLIO
- 15.3.5 RECENT DEVELOPMENT
  - 15.3.5.1 ACQUISITION
15.4 PERKINELMER INC.
- 15.4.1 COMPANY SNAPSHOT
- 15.4.2 REVENUE ANALYSIS
- 15.4.3 COMPANY SHARE ANALYSIS
- 15.4.4 PRODUCT PORTFOLIO
- 15.4.5 RECENT DEVELOPMENT
  - 15.4.5.1 PRODUCT LAUNCH
15.5 THERMO FISHER SCIENTIFIC INC.
- 15.5.1 COMPANY SNAPSHOT
- 15.5.2 REVENUE ANALYSIS
- 15.5.3 COMPANY SHARE ANALYSIS
- 15.5.4 PRODUCT PORTFOLIO
- 15.5.5 RECENT DEVELOPMENT
  - 15.5.5.1 COLLABORATION
15.6 ABBOTT
- 15.6.1 COMPANY SNAPSHOT
- 15.6.2 REVENUE ANALYSIS
- 15.6.3 PRODUCT PORTFOLIO
- 15.6.4 RECENT DEVELOPMENT
15.7 BIOCARTIS
- 15.7.1 COMPANY SNAPSHOT
- 15.7.2 REVENUE ANALYSIS
- 15.7.3 PRODUCT PORTFOLIO
- 15.7.4 RECENT DEVELOPMENT
  - 15.7.4.1 PARTNERSHIP
  - 15.7.4.2 AGREEMENT
15.8 BIO-HELIX
- 15.8.1 COMPANY SNAPSHOT
- 15.8.2 PRODUCT PORTFOLIO
- 15.8.3 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
- 15.9.1 COMPANY SNAPSHOT
- 15.9.2 REVENUE ANALYSIS
- 15.9.3 PRODUCT PORTFOLIO
- 15.9.4 RECENT DEVELOPMENTS
  - 15.9.4.1 ACQUISITION
  - 15.9.4.2 PARTNERSHIP
15.10 BIOREFERENCE
- 15.10.1 COMPANY SNAPSHOT
- 15.10.2 REVENUE ANALYSIS
- 15.10.3 PRODUCT PORTFOLIO
- 15.10.4 RECENT DEVELOPMENT
  - 15.10.4.1 ACQUISITION
15.11 ELITECHGROUP
- 15.11.1 COMPANY SNAPSHOT
- 15.11.2 PRODUCT PORTFOLIO
- 15.11.3 RECENT DEVELOPMENTS
  - 15.11.3.1 PRODUCT LAUNCH
  - 15.11.3.2 BUSINESS EXPANSION
15.12 EUROFINS SCIENTIFIC
- 15.12.1 COMPANY SNAPSHOT
- 15.12.2 REVENUE ANALYSIS
- 15.12.3 PRODUCT PORTFOLIO
- 15.12.4 RECENT DEVELOPMENT
  - 15.12.4.1 PRODUCT LAUNCH
15.13 EUGENE LABS
- 15.13.1 COMPANY SNAPSHOT
- 15.13.2 PRODUCT PORTFOLIO
- 15.13.3 RECENT DEVELOPMENT
15.14 F. HOFFMANN-LA ROCHE LTD)
- 15.14.1 COMPANY SNAPSHOT
- 15.14.2 REVENUE ANALYSIS (PARENT COMPANY)
- 15.14.3 PRODUCT PORTFOLIO
- 15.14.4 RECENT DEVELOPMENTS
  - 15.14.4.1 PRODUCT LAUNCH
15.15 GENES2ME
- 15.15.1 COMPANY SNAPSHOT
- 15.15.2 PRODUCT PORTFOLIO
- 15.15.3 RECENT DEVELOPMENT
15.16 INVITAE CORPORATION
- 15.16.1 COMPANY SNAPSHOT
- 15.16.2 REVENUE ANALYSIS
- 15.16.3 PRODUCT PORTFOLIO
- 15.16.4 RECENT DEVELOPMENTS
15.17 MAPMYGENOME
- 15.17.1 COMPANY SNAPSHOT
- 15.17.2 PRODUCT PORTFOLIO
- 15.17.3 RECENT DEVELOPMENT
15.18 MEDGENOME
- 15.18.1 COMPANY SNAPSHOT
- 15.18.2 PRODUCT PORTFOLIO
- 15.18.3 RECENT DEVELOPMENT
15.19 MYRIAD GENETICS
- 15.19.1 COMPANY SNAPSHOT
- 15.19.2 REVENUE ANALYSIS
- 15.19.3 PRODUCT PORTFOLIO
- 15.19.4 RECENT DEVELOPMENT
15.20 NATERA, INC.
- 15.20.1 COMPANY SNAPSHOT
- 15.20.2 PRODUCT PORTFOLIO
- 15.20.3 RECENT DEVELOPMENT
  - 15.20.3.1 PARTNERSHIP
15.21 OTOGENRTICS
- 15.21.1 COMPANY SNAPSHOT
- 15.21.2 PRODUCT PORTFOLIO
- 15.21.3 RECENT DEVELOPMENT
15.22 PACBIO
- 15.22.1 COMPANY SNAPSHOT
- 15.22.2 REVENUE ANALYSIS
- 15.22.3 PRODUCT PORTFOLIO
- 15.22.4 RECENT DEVELOPMENT
15.23 QIAGEN
- 15.23.1 COMPANY SNAPSHOT
- 15.23.2 PRODUCT PORTFOLIO
- 15.23.3 RECENT DEVELOPMENTS
  - 15.23.3.1 PARTNERSHIP
  - 15.23.3.2 PRODUCT LAUNCH
15.24 SEMA4 OPCO, INC.
- 15.24.1 COMPANY SNAPSHOT
- 15.24.2 REVENUE ANALYSIS
- 15.24.3 PRODUCT PORTFOLIO
- 15.24.4 RECENT DEVELOPMENT
15.25 SORENSON GENOMICS
- 15.25.1 COMPANY SNAPSHOT
- 15.25.2 PRODUCT PORTFOLIO
- 15.25.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

LIST OF TABLES

TABLE 1 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 77
TABLE 2 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 78
TABLE 3 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 78
TABLE 4 EUROPE DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 5 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 6 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 80
TABLE 7 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 80
TABLE 8 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 80
TABLE 9 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 81
TABLE 10 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 81
TABLE 11 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 81
TABLE 12 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 82
TABLE 13 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 84
TABLE 14 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 84
TABLE 15 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 84
TABLE 16 EUROPE NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 85
TABLE 17 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 86
TABLE 18 EUROPE PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 19 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 20 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 88
TABLE 21 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 88
TABLE 22 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 88
TABLE 23 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 89
TABLE 24 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 89
TABLE 25 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 89
TABLE 26 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 90
TABLE 27 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 90
TABLE 28 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 90
TABLE 29 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 91
TABLE 30 EUROPE OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 92
TABLE 31 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 96
TABLE 32 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 97
TABLE 33 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 97
TABLE 34 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 99
TABLE 35 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 99
TABLE 36 EUROPE WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 100
TABLE 37 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 101
TABLE 38 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 101
TABLE 39 EUROPE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 102
TABLE 40 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 103
TABLE 41 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 107
TABLE 42 EUROPE CANCER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 108
TABLE 43 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 108
TABLE 44 EUROPE SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 110
TABLE 45 EUROPE THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 110
TABLE 46 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 111
TABLE 47 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 112
TABLE 48 EUROPE FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 113
TABLE 49 EUROPE DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 114
TABLE 50 EUROPE HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 115
TABLE 51 EUROPE CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 116
TABLE 52 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 116
TABLE 53 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 120
TABLE 54 EUROPE HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 121
TABLE 55 EUROPE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 122
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 122
TABLE 57 EUROPE PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 123
TABLE 58 EUROPE LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 124
TABLE 59 EUROPE PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 124
TABLE 60 EUROPE GENETIC TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 130
TABLE 61 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
TABLE 62 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 130
TABLE 63 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 131
TABLE 64 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
TABLE 65 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 131
TABLE 66 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 131
TABLE 67 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 131
TABLE 68 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 132
TABLE 69 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 132
TABLE 70 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 132
TABLE 71 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 133
TABLE 72 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 133
TABLE 73 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 133
TABLE 74 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 133
TABLE 75 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 134
TABLE 76 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 134
TABLE 77 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 134
TABLE 78 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
TABLE 79 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 134
TABLE 80 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 135
TABLE 81 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
TABLE 82 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 135
TABLE 83 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 135
TABLE 84 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 135
TABLE 85 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 136
TABLE 86 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 136
TABLE 87 EUROPE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 136
TABLE 88 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 137
TABLE 89 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 137
TABLE 90 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 137
TABLE 91 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 138
TABLE 92 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 138
TABLE 93 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
TABLE 94 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 139
TABLE 95 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 139
TABLE 96 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
TABLE 97 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 140
TABLE 98 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 140
TABLE 99 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 140
TABLE 100 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 141
TABLE 101 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 141
TABLE 102 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 141
TABLE 103 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 142
TABLE 104 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 142
TABLE 105 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 142
TABLE 106 GERMANY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
TABLE 107 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 143
TABLE 108 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 143
TABLE 109 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 143
TABLE 110 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 143
TABLE 111 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 143
TABLE 112 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 144
TABLE 113 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
TABLE 114 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 144
TABLE 115 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 144
TABLE 116 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 145
TABLE 117 GERMANY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 145
TABLE 118 GERMANY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 145
TABLE 119 GERMANY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 146
TABLE 120 GERMANY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 146
TABLE 121 GERMANY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 146
TABLE 122 GERMANY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 147
TABLE 123 GERMANY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 147
TABLE 124 GERMANY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 147
TABLE 125 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 148
TABLE 126 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 148
TABLE 127 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 148
TABLE 128 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
TABLE 129 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 149
TABLE 130 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 149
TABLE 131 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 149
TABLE 132 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 150
TABLE 133 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 150
TABLE 134 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 150
TABLE 135 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 151
TABLE 136 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 151
TABLE 137 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 151
TABLE 138 FRANCE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
TABLE 139 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 152
TABLE 140 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 152
TABLE 141 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 152
TABLE 142 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
TABLE 143 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 152
TABLE 144 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 153
TABLE 145 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 153
TABLE 146 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 153
TABLE 147 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 153
TABLE 148 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 154
TABLE 149 FRANCE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 154
TABLE 150 FRANCE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 154
TABLE 151 FRANCE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 155
TABLE 152 FRANCE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 155
TABLE 153 FRANCE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 155
TABLE 154 FRANCE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 156
TABLE 155 FRANCE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 156
TABLE 156 FRANCE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 156
TABLE 157 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 157
TABLE 158 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 157
TABLE 159 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 157
TABLE 160 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 158
TABLE 161 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 158
TABLE 162 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 158
TABLE 163 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 158
TABLE 164 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 158
TABLE 165 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 159
TABLE 166 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 159
TABLE 167 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 159
TABLE 168 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 160
TABLE 169 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 160
TABLE 170 U.K. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
TABLE 171 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 160
TABLE 172 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 161
TABLE 173 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 161
TABLE 174 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
TABLE 175 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 161
TABLE 176 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 161
TABLE 177 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 162
TABLE 178 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 162
TABLE 179 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 162
TABLE 180 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 162
TABLE 181 U.K. GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 163
TABLE 182 U.K. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 163
TABLE 183 U.K. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 163
TABLE 184 U.K. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 164
TABLE 185 U.K. GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 164
TABLE 186 U.K. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 164
TABLE 187 U.K. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 165
TABLE 188 U.K. GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 165
TABLE 189 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
TABLE 190 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 166
TABLE 191 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 166
TABLE 192 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 167
TABLE 193 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 167
TABLE 194 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 167
TABLE 195 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 167
TABLE 196 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 168
TABLE 197 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 168
TABLE 198 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 168
TABLE 199 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 169
TABLE 200 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 169
TABLE 201 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 169
TABLE 202 RUSSIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 169
TABLE 203 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 170
TABLE 204 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 170
TABLE 205 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 170
TABLE 206 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
TABLE 207 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 170
TABLE 208 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 171
TABLE 209 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 171
TABLE 210 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 171
TABLE 211 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 171
TABLE 212 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 172
TABLE 213 RUSSIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 172
TABLE 214 RUSSIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 172
TABLE 215 RUSSIA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 173
TABLE 216 RUSSIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 173
TABLE 217 RUSSIA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 173
TABLE 218 RUSSIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 174
TABLE 219 RUSSIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 174
TABLE 220 RUSSIA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 174
TABLE 221 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
TABLE 222 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 175
TABLE 223 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 175
TABLE 224 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
TABLE 225 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 176
TABLE 226 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 176
TABLE 227 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 176
TABLE 228 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 176
TABLE 229 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 177
TABLE 230 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 177
TABLE 231 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 177
TABLE 232 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 178
TABLE 233 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 178
TABLE 234 ITALY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 178
TABLE 235 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 178
TABLE 236 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 179
TABLE 237 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 179
TABLE 238 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 179
TABLE 239 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 179
TABLE 240 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 179
TABLE 241 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 180
TABLE 242 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 180
TABLE 243 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 180
TABLE 244 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 180
TABLE 245 ITALY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 181
TABLE 246 ITALY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 181
TABLE 247 ITALY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 181
TABLE 248 ITALY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 182
TABLE 249 ITALY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 182
TABLE 250 ITALY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 182
TABLE 251 ITALY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 183
TABLE 252 ITALY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 183
TABLE 253 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 184
TABLE 254 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 184
TABLE 255 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 184
TABLE 256 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 185
TABLE 257 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 185
TABLE 258 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 185
TABLE 259 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 185
TABLE 260 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 185
TABLE 261 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 186
TABLE 262 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 186
TABLE 263 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 186
TABLE 264 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 187
TABLE 265 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 187
TABLE 266 SPAIN NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 187
TABLE 267 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 187
TABLE 268 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 188
TABLE 269 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 188
TABLE 270 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 188
TABLE 271 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 188
TABLE 272 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 188
TABLE 273 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 189
TABLE 274 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 189
TABLE 275 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 189
TABLE 276 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 189
TABLE 277 SPAIN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 190
TABLE 278 SPAIN POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 190
TABLE 279 SPAIN DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 190
TABLE 280 SPAIN MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 191
TABLE 281 SPAIN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 191
TABLE 282 SPAIN RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 191
TABLE 283 SPAIN CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 192
TABLE 284 SPAIN GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 192
TABLE 285 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 193
TABLE 286 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 193
TABLE 287 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 193
TABLE 288 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 194
TABLE 289 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 194
TABLE 290 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 194
TABLE 291 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 194
TABLE 292 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 195
TABLE 293 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 195
TABLE 294 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 195
TABLE 295 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 196
TABLE 296 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 196
TABLE 297 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 196
TABLE 298 TURKEY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 196
TABLE 299 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 197
TABLE 300 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 197
TABLE 301 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 197
TABLE 302 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 197
TABLE 303 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 197
TABLE 304 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 198
TABLE 305 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 198
TABLE 306 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 198
TABLE 307 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 198
TABLE 308 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 199
TABLE 309 TURKEY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 199
TABLE 310 TURKEY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 199
TABLE 311 TURKEY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 200
TABLE 312 TURKEY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 200
TABLE 313 TURKEY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 200
TABLE 314 TURKEY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 201
TABLE 315 TURKEY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 201
TABLE 316 TURKEY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 201
TABLE 317 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 202
TABLE 318 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 202
TABLE 319 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 202
TABLE 320 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 203
TABLE 321 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 203
TABLE 322 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 203
TABLE 323 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 203
TABLE 324 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 204
TABLE 325 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 204
TABLE 326 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 204
TABLE 327 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 205
TABLE 328 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 205
TABLE 329 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 205
TABLE 330 NETHERLANDS NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 205
TABLE 331 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 206
TABLE 332 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 206
TABLE 333 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 206
TABLE 334 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 206
TABLE 335 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 207
TABLE 336 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 207
TABLE 337 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 207
TABLE 338 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 207
TABLE 339 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 207
TABLE 340 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 208
TABLE 341 NETHERLANDS GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 208
TABLE 342 NETHERLANDS POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 208
TABLE 343 NETHERLANDS DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 209
TABLE 344 NETHERLANDS MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 209
TABLE 345 NETHERLANDS GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 209
TABLE 346 NETHERLANDS RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 210
TABLE 347 NETHERLANDS CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 210
TABLE 348 NETHERLANDS GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 210
TABLE 349 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 211
TABLE 350 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 211
TABLE 351 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 211
TABLE 352 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 212
TABLE 353 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 212
TABLE 354 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 212
TABLE 355 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 212
TABLE 356 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 213
TABLE 357 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 213
TABLE 358 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 213
TABLE 359 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 214
TABLE 360 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 214
TABLE 361 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 214
TABLE 362 SWITZERLAND NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 214
TABLE 363 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 215
TABLE 364 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 215
TABLE 365 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 215
TABLE 366 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 215
TABLE 367 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 215
TABLE 368 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 216
TABLE 369 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 216
TABLE 370 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 216
TABLE 371 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 216
TABLE 372 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 217
TABLE 373 SWITZERLAND GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 217
TABLE 374 SWITZERLAND POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 217
TABLE 375 SWITZERLAND DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 218
TABLE 376 SWITZERLAND MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 218
TABLE 377 SWITZERLAND GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 218
TABLE 378 SWITZERLAND RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 219
TABLE 379 SWITZERLAND CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 219
TABLE 380 SWITZERLAND GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 219
TABLE 381 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 220
TABLE 382 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 220
TABLE 383 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 220
TABLE 384 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 221
TABLE 385 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 221
TABLE 386 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 221
TABLE 387 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 221
TABLE 388 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 222
TABLE 389 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 222
TABLE 390 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 222
TABLE 391 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 223
TABLE 392 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 223
TABLE 393 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 223
TABLE 394 BELGIUM NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 223
TABLE 395 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 224
TABLE 396 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 224
TABLE 397 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 224
TABLE 398 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 224
TABLE 399 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 224
TABLE 400 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 225
TABLE 401 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 225
TABLE 402 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 225
TABLE 403 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 225
TABLE 404 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 226
TABLE 405 BELGIUM GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 226
TABLE 406 BELGIUM POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 226
TABLE 407 BELGIUM DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 227
TABLE 408 BELGIUM MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 227
TABLE 409 BELGIUM GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 227
TABLE 410 BELGIUM RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 228
TABLE 411 BELGIUM CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 228
TABLE 412 BELGIUM GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 228
TABLE 413 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 229
TABLE 414 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 229
TABLE 415 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 229

LIST OF FIGURES

FIGURE 1 EUROPE GENETIC TESTING MARKET: SEGMENTATION 38
FIGURE 2 EUROPE GENETIC TESTING MARKET: DATA TRIANGULATION 41
FIGURE 3 EUROPE GENETIC TESTING MARKET: DROC ANALYSIS 42
FIGURE 4 EUROPE GENETIC TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 43
FIGURE 5 EUROPE GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS 43
FIGURE 6 EUROPE GENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS 45
FIGURE 7 EUROPE GENETIC TESTING MARKET: DBMR MARKET POSITION GRID 46
FIGURE 8 EUROPE GENETIC TESTING MARKET: APPLICATION COVERAGE GRID 47
FIGURE 9 EUROPE GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS 48
FIGURE 10 EUROPE GENETIC TESTING MARKET: SEGMENTATION 52
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 53
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENETIC TESTING MARKET IN 2022 & 2029 53
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 54
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE GENETIC TESTING MARKET 64
FIGURE 15 EUROPE GENETIC TESTING MARKET: BY TYPE, 2021 74
FIGURE 16 EUROPE GENETIC TESTING MARKET: BY TYPE, 2022-2029 (USD MILLION) 75
FIGURE 17 EUROPE GENETIC TESTING MARKET: BY TYPE, CAGR (2022-2029) 75
FIGURE 18 EUROPE GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE 76
FIGURE 19 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2021 93
FIGURE 20 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION) 94
FIGURE 21 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2022-2029) 94
FIGURE 22 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE 95
FIGURE 23 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2021 104
FIGURE 24 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2022-2029 (USD MILLION) 105
FIGURE 25 EUROPE GENETIC TESTING MARKET: BY DISEASES, CAGR (2022-2029) 105
FIGURE 26 EUROPE GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE 106
FIGURE 27 EUROPE GENETIC TESTING MARKET: BY END USER, 2021 117
FIGURE 28 EUROPE GENETIC TESTING MARKET: BY END USER, 2022-2029 (USD MILLION) 118
FIGURE 29 EUROPE GENETIC TESTING MARKET: BY END USER, CAGR (2022-2029) 118
FIGURE 30 EUROPE GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE 119
FIGURE 31 EUROPE GENETIC TESTING MARKET: SNAPSHOT (2021) 126
FIGURE 32 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021) 127
FIGURE 33 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2022 & 2029) 127
FIGURE 34 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021 & 2029) 128
FIGURE 35 EUROPE GENETIC TESTING MARKET: BY TYPE (2022-2029) 128
FIGURE 36 EUROPE GENETIC TESTING MARKET: COMPANY SHARE 2021 (%) 229